PPARA and metabolic dysfunction-associated steatotic liver disease: Thus, Ppara-null mice were reportedly defective in fatty acid utilization and displayed a fatty liver phenotype [30], and activation of PPARα with an agonist compound has been suggested as a therapeutic strategy for NAFLD [31].